Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation
Author:
Tembo G.ORCID, Mayuni M., Kamng'ona R., Chimgoneko L., Chiwala G.ORCID, Sichone S., Galafa B.ORCID, Thole F., Mkandawire C., Chirwa A.E., Nsomba E., Nkhoma V., Ngoliwa C., Toto N.ORCID, Makhaza L., Muyaya A., Kudowa E., Henrion M.Y.R.ORCID, Dula D., Morton B.ORCID, Chikaonda T.ORCID, Gordon S.B.ORCID, Jambo K.C.ORCID
Reference35 articles.
1. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016;Troeger;Lancet Infect Dis,2018 2. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15;Wahl;Lancet Glob Health,2018 3. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality;Harboe;Clin Infect Dis,2014 4. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study;Moore;Lancet Respir Med,2016 5. Population impact and effectiveness of sequential 13-valent pneumococcal conjugate and monovalent rotavirus vaccine introduction on infant mortality: prospective birth cohort studies from Malawi;King;BMJ Glob Health,2020
|
|